Emotional distress in chronic hepatitis C patients not receiving antiviral therapy

J Hepatol. 2002 Mar;36(3):401-7. doi: 10.1016/s0168-8278(01)00280-x.

Abstract

Background/aims: The aim of our study was to determine the prevalence, type, and severity of emotional distress in a large group of consecutive chronic hepatitis C (CHC) patients not receiving anti-viral therapy.

Methods: The brief symptom inventory and a 67-item questionnaire with the SF-36 embedded within it were used to study 220 outpatients with compensated CHC.

Results: Seventy-seven (35%) participants reported significantly elevated global severity index (GSI) T-scores compared to an expected frequency of 10% in population controls. In addition, significantly elevated depression, anxiety, somatization, psychoticism, and obsessive-compulsive subscale T-scores were reported in 28-40% of subjects. Subjects with an active psychiatric co-morbidity had significantly higher GSI and subscale T-scores compared to subjects with active medical co-morbidities and subjects without medical or psychiatric co-morbidities (P<0.01). However, patients with CHC alone also had a higher frequency of elevated GSI T-scores compared to population controls (20 versus 10%). GSI and subscale T-scores were strongly associated with SF-36 summary scores (P<0.001).

Conclusions: Clinically significant emotional distress was reported in 35% of CHC patients not receiving antiviral therapy. In addition to depression, a broad array of psychological symptoms were observed. Further investigation into the etiopathogenesis and treatment of emotional distress in CHC patients is warranted.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Affective Symptoms / diagnosis
  • Affective Symptoms / epidemiology*
  • Aged
  • Antiviral Agents / administration & dosage*
  • Attitude to Health
  • Comorbidity
  • Data Collection
  • Depression / diagnosis
  • Depression / epidemiology
  • Female
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / epidemiology
  • Hepatitis C, Chronic* / psychology
  • Humans
  • Interferon-alpha / administration & dosage*
  • Male
  • Middle Aged
  • Prevalence
  • Quality of Life

Substances

  • Antiviral Agents
  • Interferon-alpha